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Several clinical observations have confirmed that a donor immune-mediated anti-malignancy effect, called
graft-versus-leukemia or graft-versus-tumor, occurs following allogeneic hematopoietic stem cell transplant-
ation. While the potential antitumor effect mediated by donor lymphocytes has been established in many hema-
tological malignancies, its efficacy in inducing clinically meaningful responses in solid tumors has been largely
unexplored despite evidence of its potential benefit in experimental animal models. Only in recent years has the
investigational application of non-myeloablative stem cell transplantation in patients with refractory non-hema-
tological cancers proved that a graft-versus-tumor effect can be generated in patients with metastatic renal cell
cancer and possibly with other solid tumors. In the present article we review the biological basis, development
and early clinical results of this novel immunotherapeutic approach for solid tumors.
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Introduction
In the last two decades, various immunological strategies have
been assessed to stimulate antitumor immunity in cancer patients,
including vaccination with peptide- or tumor lysate-pulsed den-
dritic cells or cytokine-mediated immunotherapy [1–3]. While to
date these approaches have resulted in limited clinical benefits,
they have established proof-of-concept of the efficacy of immu-
notherapy for cancer, laying the foundation for the development
of novel immunotherapeutic strategies. In this field, there is a
growing perception that the graft-versus-malignancy reaction that
follows allogeneic hematopoietic stem cell transplantation (HSCT)
is arguably the most potent form of cancer immunotherapy cur-
rently in clinical use [4].
Graft-versus-leukemia effect
One of the most important advances in the field of HSCT for
leukemia has been the observation that even the most intense con-
ditioning regimen does not reliably eliminate leukemia clones and
that patients experiencing acute or chronic graft-versus-host dis-
ease (GVHD) have a lower relapse rate than comparable patients
without such complications [5–7]. This led to the speculation that
the alloresponse of donor lymphocytes against malignant cells
(graft-versus-leukemia, GVL) has a major therapeutic role in the
setting of allo-HSCT [8].
The most striking and direct evidence supporting the GVL
effect is the observation that patients with chronic myeloid leu-
kemia (CML) and other hematological malignancies relapsing
after allogeneic transplantation can be re-induced into complete
remission by a donor lymphocyte infusion (DLI) [9–11]. The
GVL effect appears mediated by donor T lymphocytes and/or
natural killer (NK) cells recognizing host antigens presented in the
context of the major histocompatibily complex (MHC) class I and
II molecules of leukemic cells [12]; it has been suggested that the
tissue distribution/restriction pattern of the target antigen will ulti-
mately determine whether the GVT response is accompanied by
GVHD [13].
An antitumor effect mediated by the donor immune system is
well recognized also in advanced lymphoid malignancies [14].
The graft-versus-lymphoma effect appears to be particularly import-
ant for a reduced incidence of relapse after allogeneic HSCT [14,
15].
Based on the hypothesis that an immune-mediated antitumor
effect following allogeneic HSCT might be sufficient in promot-
ing cure of some hematological malignancies, several authors began
to explore the use of less-intensive preparative regimens capable
of providing sufficient immunosuppression to achieve sustained
engraftment of donor hematopoietic cells without ablating host
hematopoiesis. This novel approach, named non-myeloablative
stem cell transplantation (NST), offers the theoretical advantage
of low treatment-related mortality (TRM) and morbidity and can
be utilized also in patients not eligible for conventional myelo-
ablative conditioning regimens because of advanced age or comorbid
diseases. The post-transplantation infusion of donor lymphocytes
is usually part of NST protocols; DLIs are given to convert mixed
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to full donor chimerism and to promote the immune antitumor
effect in non-responding patients [16].
NST has proved to be effective in the treatment of various
hematological malignancies [14, 17–19] and is now under investi-
gation also in solid tumors as detailed below.
Graft-versus-(solid) tumor effect
Several investigators have documented immune-mediated anti-
tumor effects in experimental animal models of allogeneic trans-
plantation. A GVT effect analogous to that seen in the GVL
response was first demonstrated by Moskovitch and Slavin [20]
against spontaneous lymphosarcoma in New Zealand black mouse
hybrids following induction of host-versus-graft transplantation
tolerance. Subsequently the same group documented the genera-
tion of GVT effect in a murine mammary carcinoma model of
BALB/c mice, using naive MHC-mismatched splenocytes [21, 22].
In this model, survival of tumor-bearing hosts was significantly
prolonged after transplantation of splenocytes with different grades
of HLA disparities. In particular, 21 of 22 secondary recipients of
tumor-bearing mice grafted with allogeneic spleen cells did not
develop lung metastases, in contrast to syngeneic recipients. This
finding provided evidence that minimal residual disease can be
effectively eradicated by allogeneic HSCT and that GVT is more
effective in the presence of a low tumor burden. The GVT effect
can be enhanced by pre-immunization of donor lymphocytes, as
shown in a murine mammary carcinoma experimental system, in
which a higher rate of survival was observed among mice receiv-
ing lymphocytes primed with tumor cells, as compared with mice
treated with unmanipulated donor cells [23]. Taken together these
observations offer clinicians promising perspectives, since the
higher efficacy was not coupled with an equivalent risk of develop-
ing acute GVHD, suggesting that it is possible to generate lympho-
cytes specific for neoplastic cells.
For several reasons, an allogeneic-based immunotherapy for
metastatic solid tumors could theoretically have efficacy superior
to approaches designed to enhance autologous immunity [4]. First,
a healthy donor immune system has yet to develop tolerance
against tumor antigens and, once tolerance comes out, regular
boosts of immune cells (i.e. DLI) with antitumor potential can
subsequently be added. Secondly, donor T cells can be capable of
recognizing a wide pool of antigens including minor histocompat-
ibility antigens. In addition, some characteristics of epithelial
tumor cells, such as their origin from normal tissues that are a
target for GVHD and the high degree of MHC class I expression,
may favor the generation of a GVT effect.
Allogeneic HSCT for treatment of solid tumors
Despite laboratory evidence of a GVT effect and of a possible role
of allogeneic HSCT against solid tumors, this approach has been
investigated in humans only recently after the demonstration that
sustained engraftment of donor hematopoietic stem cells can be
accomplished with the use of NST. In fact, because of the asso-
ciated morbidity and mortality, conventional myeloablative high-
dose chemotherapy and HSCT is restricted to young, medically fit
patients, thus excluding the vast majority of cancer patients from
this therapy. In addition, high doses of cytotoxic drugs are not
required as patients with chemo-refractory diseases are treated.
Renal cell carcinoma
Early clinical trials aimed at exploring GVT following NST were
focused on metastatic renal cell carcinoma (RCC) as this tumor is
known to be immunogenic and sensitive to immune-based thera-
pies [24]. RCC may be susceptible to a GVT effect as T lympho-
cytes have been shown to be an important component of the
antitumor immunological response. In addition to the known
effects of cytokines in this disease, it has been reported that clon-
ally expanded cytotoxic T lymphocytes (CTLs) are present in
primary and metastatic RCC specimens and demonstrate HLA-
restricted cytotoxicity against RCC cell lines [25]. These antigen-
specific CTLs have also been shown to persist in vivo [26]. To
optimize the possibility of generating a GVT effect in vivo, rapid
and complete engraftment of the donor immune system is required
[27]. This goal was achieved in pioneering studies by Childs and
coworkers with the use of: (i) a fludarabine–cyclophosphamide
highly immunosuppressive conditioning regimens along with a
rapid withdrawal of the post-transplantation immunosuppression;
(ii) peripheral blood mobilized stem cells which contain high T-cell
doses; and (iii) the possible post-transplantation DLI to convert
mixed to full donor T-cell chimerism [27].
Ten of the first 19 patients [28] and more recently 19 of 42
patients [29] who received NST at the National Institute of Health
had a measurable response, and four patients enjoyed complete,
long-lasting responses. Importantly, disease regression typically
occurred after ciclosporin had been withdrawn and chimerism had
transitioned from mixed to predominantly donor T cell. Acute
GVHD occurred concomitantly with tumor regression in several
patients. However, acute GVHD was not always required for the
generation of a GVT effect as one patient had a complete response
without GVHD and several others had tumor regression months
after acute GVHD had resolved. This clinical observation, along
with in vitro studies on CTL populations of donor origin [4], sup-
ports the working hypothesis that distinct T-cell populations,
capable of recognizing tumor-restricted antigens or molecules
shared by both the tumor and the normal tissues, may be involved
in producing tumor response following NST. Interestingly, it was
observed that only clear-cell carcinoma and not other histologies
appears to be a target of a GVT effect. Moreover, patients who had
failed to respond to interferon-α before NST had disease response
when they were retreated with interferon-α after transplantation.
Other reports have provided further evidence that RCC may be
susceptible to a GVT effect [30, 31]. In particular, Rini et al. [31]
observed partial responses in four of 12 patients treated with a
fludarabine–cyclophosphamide regimen similar to that used by
Childs et al. Importantly, the antitumor effect was observed only
after 100% donor T-cell chimerism and 6 months after transplant-
ation in all four patients [27].
Overall the reported experiences [28, 30–32] in RCC suggest
that younger, otherwise healthy patients with low-volume, slow-
growing disease are the best candidates for allogeneic transplant-
ation.
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Solid tumors other than RCC
A small number of reports of GVT effects in humans following
HSCT from HLA-matched family donors provide evidence that
allogeneic antitumor effects can be induced against solid tumors
other than RCC as summarized in Table 1. In a pivotal study, Eibl
et al. [33] firstly described a GVT effect in a woman with refract-
ory metastatic breast cancer (BC) treated with allogeneic HSCT.
The patient experienced regression of liver metastasis associated
with the onset of acute GVHD. In addition, the authors demon-
strated, in the post-transplantation phase, an expansion of CTLs
reactive against patient hematopoietic minor histocompatibility
antigens which were capable of lysing partially HLA-matched BC
cell lines. More recently, further evidence of a clinically meaning-
ful GVT effect against BC has been reported by Ueno et al. [34],
Bregni et al. [30] and Carella et al. [35].
Single-case reports and small series of patients with cancer of
various histologies treated with allogeneic HSCT consist of carcin-
oma of the ovary [36, 37], lung [38], colorectum [39] and prostate
[37], as well as sarcoma [32]. In most cases responses were
accompanied by the occurrence of acute GVHD. Table 1 summar-
izes the results of published reports in which different solid tumors
appeared to be susceptible to allogeneic immune attack following
allogeneic HSCT.
Although a GVT response has been shown in vitro in two cases
of metastatic melanoma [40], preliminary results of NST in this
disease are discouraging as median survival following NST was
100 days in 25 patients reported by Childs et al. [41]. The likeli-
hood of a clinically meaningful GVT effect appears low, as only
five patients had a transient conditioning-related tumor regres-
sion. This unfavorable experience highlights the need for altern-
ative immune-based strategies in treatment-refractory melanoma
[42].
Limitation of NST for solid tumors and present 
clinical approaches
While stimulating results have been reported mostly in RCC fol-
lowing allogeneic transplantation, it is important to consider these
responses in the context of the clinical therapeutic index of the
procedure taking into account the risks of transplantation-related
morbidity and mortality. Although in NST the regimen-related
toxicities appear to be fewer than in conventional high-dose myelo-
ablative transplants, the risk of TRM is still in the range of 10–20%,
possibly higher in patients with poor performance status (PS),
within 100 days from graft. Given the potential for life-threatening
complications, early trials of allogeneic HSCT for solid malig-
nancies involved patients with progressive metastatic disease,
often with large tumor masses and a poor PS, in whom prior
treatments had failed. Such patients are more frail and the risk of
transplantation-related complications and mortality is higher [32].
In addition, the efficacy of immunotherapy with allogeneic
lymphocytes requires the full engraftment of the donor lym-
phocytes [28]. For these reasons and because of the frequent
requirement for a long post-transplantation immune suppression,
a major limitation of NST in solid tumors is the delay in the anti-
tumor response due to the time required for the recovery of cell-
mediated immunity and for the generation of T-cell response.
Therefore, patients with poor PS and/or rapidly progressing meta-
static disease are not likely to live long enough for the generation
of a GVT effect and should not be treated with NST. Ongoing
studies of NST are in fact selecting patients at an early stage of
metastatic disease with a lower tumor burden. Intensified chemo-
therapeutic treatments in selected patients with chemosensitive
diseases [35] or surgical debulking [28] are currently utilized to
reduce the tumor mass before NST.
Study in RCC [28, 30, 31] used substantial doses of alkylating
agents in their preparative regimens placing all patients at risk of
bleeding and infection. The Seattle group have also seen dramatic
responses of RCC after NST using low-dose, i.e. 30 mg/m2 × 3,
fludarabine plus low-dose, i.e. 2 Gy, total-body irradiation [43].
This lower-dose regimen does not cause pancytopenia and can be
managed on an outpatient basis. Whether response rates will be
different with the less-toxic Seattle approach is under investigation.
However, the optimal non-myeloablative preparative regimen for
patients with solid tumors undergoing allografting is likely to
depend on several factors, including the aggressiveness of the
patient’s malignancy and the immunocompetence of the recipient.
Immune-compromised patients, such as those previously treated
with intensified chemoradiotherapy, could require less intensive
immunosuppression to achieve engraftment than a fully immuno-
competent recipient [44]. In contrast, in patients with highly pro-
liferative malignancies, a more aggressive conditioning regimen,
along with a rapid tapering of post-transplantation immune sup-
pression, may favor the generation of a GVT effect more rapidly.
Ongoing studies will hopefully clarify these points and provide
information on the optimal post-transplantation immunosuppres-
sion and on the incidence of long-term complications of NST.
Based on the results obtained in hematological malignancies,
escalating doses of DLI have been utilized in patients with solid
tumors not responding to NST and without signs of GVHD for
promoting the GVT effect. While some patients experienced tumor
regression following this procedure, the role of post-transplantation
DLI infusion is not clearly defined in this setting [30, 45]. In par-
ticular, the dose of T cells to induce a clinical response and the
optimal time interval from allograft to DLI remain to be deter-
mined.
The heterogeneous results in different tumor histotypes using
NST indicate that GVT effects are likely to vary considerably
from one disease to another. At present, the lack of biological
information on tumor target antigens and immune mediators for
GVT does not allow us to predict which diseases will respond to
this approach. For this reason increasing numbers of investigators
are performing NST in a wide variety of solid cancers. In this
regard, it is mandatory that patients be treated in institutions with
proven experience in this setting and in the context of specific
clinical trials designed to address major clinical and biological
issues. In particular, great attention should be paid to understand-
ing better the mechanisms of immune escape used by tumor cells
and how to restore immune competence against cancer. This
information is necessary for designing future trials.
Most investigations of NST in solid tumors have required an
HLA-matched sibling as stem cell source therefore greatly limit-
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ing the number of candidates for this procedure. However, because
of the increased risk of GVHD and TRM associated with allo-
geneic HSCT from HLA-matched unrelated donor (MUD) and
the limited experience of NST in solid tumors so far available, it
would be very desirable that MUD transplants should not be per-
formed at this stage to avoid any possible confounding element for
the evaluation of results.
Allogeneic HSCT for solid tumors in 
perspective
Clinical studies reported so far provide proof-of-principle that
allogeneic T cells can induce clinically relevant GVT effects in
RCC and other solid tumors. However, it is already clear that NST
without the addition of innovative improvements is unlikely to be
a major therapeutic breakthrough for patients with metastatic solid
tumors. In the near future the major challenge for investigators in
this field will be to understand how to drive the donor immune
system in a specific fashion against antigens exclusively or prefer-
entially presented by tumor cells without damaging normal
somatic host cells [46]. In other words: can the GVT effect be
maximized while GVHD is avoided or minimized? Several lines
of research are exploring these issues from different sides.
One possibility to enhance GVT is utilizing donor cells activated
against tumor alloantigens. Animal studies have shown that immun-
ization of allogeneic bone marrow transplant recipients with
tumor cell vaccines enhances GVT activity without exacerbating
GVHD [47, 48]. Furthermore, in a mouse model of mammary car-
cinoma, Morecki et al. [23] demonstrated that pre-immunization
with minor histocompatibility antigen-mismatched tumor or spleen
cells was capable of activating effector cells to induce an anti-
tumor response. These experimental results provide the scientific
background to considering the possibility of using donor lympho-
cytes primed ex vivo against tumor cells as a new clinical tool for
eradicating residual disease or in cases in which naive allogeneic
cells have not been able to effectively reduce the tumor mass. In
this setting immunization of healthy donors with recipient-derived
tumor products before collecting stem cells appear less applicable
both for safety considerations and because of the risk of enhancing
GVHD along with GVT effects [49].
In hematological malignancies it has been already shown that
leukemia-specific CTLs generated after allogeneic HSCT are
important in maintaining the state of remission [50]. More import-
antly, Falkenburg et al. [51] demonstrated that in a patient with
CML relapsing after allogeneic HSCT and resistant to DLI, treat-
ment with ex vivo-generated leukemia-reactive CTLs achieved
complete response. Several antigens potentially targeted by allo-
reactive lymphocytes have been identified in selected solid tumors.
However, within the same tumor and at different stages of the
disease, the expression of tumor-associated antigen may vary con-
siderably, thus rendering the production of antigen-specific CTLs
a rather difficult task. It has been recently shown that CTLs can be
effectively generated using the whole tumor cell, which allows
epitopes to be selected that are immunogenic in the context of the
individual CTL repertoire [52]. The generation of CTLs with
multiple specificities should theoretically diminish the possibility
of selecting for escape variants by the poor immunogenicity of
cancer cells in vivo. This approach could well be applicable in
solid tumors when target antigens are unknown. In this regard, the
same authors have recently demonstrated the feasibility of induc-
ing ex vivo the generation of donor-derived CTLs directed
towards malignant cells from different solid tumor histotypes and
displaying low reactivity towards patients’ non-malignant cells
[53]. From this point of view, preclinical evidence suggests that a
lymphopenic host may represent a favorable clinical setting for
active immunization or cellular therapy [54]. Although conducted
in the autologous setting, a recent study by Dudley et al. [55]
has provided for the first time evidence of cancer regression by
the adoptive transfer of tumor-reactive T cells directed against
melanoma antigens in patients receiving a non-myeloablative,
highly immunosuppressive conditioning regimen. This novel
approach resulted in the persistent clonal repopulation of cancer
patients, with the transferred cells proliferating in vivo. The
adoptive transfer of specifically immune rather than naive tumor-
reactive T-cell populations may reduce the risk of GVHD.
While the adverse manifestations of GVHD are related to the
number of T cells in the stem cell inoculum, T-cell depletion
strategies designed to avoid excessive GVHD are currently under
refinement. They include the delayed T-cell add-back strategy
[56], the use of suicide gene systems [57] and selective CD8+
depletion [58]. The latter approach is based on the observation that
both CD4+ and CD8+ cells contribute to GVHD but that CD4+
cells in the absence of CD8+ cells can still provide a GVT effect
[59]. Overall, T-cell depletion approaches can significantly
reduce the risk of GVHD but do not provide definitive evidence
of improving the therapeutic index of allogeneic transplantation.
In fact, they may increase the risk of rejection and delay T-cell
chimerism, thus reducing the GVT effect.
Administration, after HSCT, of various interleukins, including
IL-1 [60] and IL-11 [61], or procedures capable of interfering with
immunoregulatory mechanisms [62, 63], proved to be effective in
animal models in inhibiting GVHD while preserving or enhancing
GVT. Studies in humans are ongoing. Finally, investigation of allo-
reactive NK cells is desirable as these cells are capable of mediat-
ing GVL effects in acute myeloid leukemia without inducing
GVHD [64].
In summary, the ability of NST to implant a new immune
system into a recipient opens new possibilities for treating hema-
tological malignancies and hopefully also solid tumors. NST can
be viewed, in perspective, as a platform for adoptive immuno-
therapy (Figure 1). The donor immune system provided by NST
can in fact permit the repeated infusion of alloimmune lympho-
cytes, tumor-specific T cells or NK cells from the donor without
risking their rejection. These new concepts will have to be developed
within carefully planned clinical studied. We must keep in mind
that NST for solid tumors is still in its infancy, as many basic
clinical questions have yet to be answered.
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Note added in proof
Additional evidence of a GVT effect in patients with RCC and
other solid tumors (including pancreatic carcinoma) has been
reported recently.
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